Trudeau M, Sinclair SE, Clemons M, et al. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systemic review. Cancer Treat Rev 2005;31:283–302.
106.
Chen AM, Meric-Berstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005;103:689–695.
107.
Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930–942.
108.
Albain K, Green S, Ravdin P, et al. Overall survival after cyclophosphamide, adriamycin, 5-FU, and tamoxifen is superior to tamoxifen alone in post-menopausal, receptor(+), node(+) breast cancer: new findings from phase III Southwest Oncology Group Intergroup Trial S8814 (INT-0100). Proc Am Soc Clin Oncol 2001;20:94(abst).
109.
Fisher B, Digman J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor–positive breast cancer. J Natl Cancer Inst 1997;89:1673–1682.
110.
Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:60–62.
111.
Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28:509–518.
112.
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.
113.
Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: Devita VT, Hellman S, Rosenberg S, eds. Cancer principles and practice of oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1651–1717.
114.
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.
115.
Early Breast Cancer Trialists’ Collaborative Group. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008;371:29–40.
116.
Dhodapkar MV, Ingle JN, Cha SS, et al. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials. Cancer 1996;77:683–690.
117.
Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Oncology 1997;11:34–36.
118.